SCHEMBL19633033

SCHEMBL19633033

CC(C)c1ccccc1-n1nc(C(=O)O)c(Br)c1-c1nc(-c2cccc(S(C)(=O)=O)c2)no1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
S1PR1 P21453 1/20 0.44
CA2 P00918 3/20 0.42
CA9 Q16790 3/20 0.42
CA12 O43570 2/20 0.42
CA1 P00915 2/20 0.42
HSP90AA1 P07900 3/20 0.38
CPT2 P23786 1/20 0.36
CPT1A P50416 1/20 0.36
NPC1 O15118 2/20 0.35
L3MBTL1 Q9Y468 2/20 0.35
RAB9A P51151 2/20 0.35
KMT2A Q03164 1/20 0.35
HSP90B1 P14625 2/20 0.35
TRAP1 Q12931 2/20 0.35
MMP12 P39900 1/20 0.35
TP53 P04637 1/20 0.35
POLB P06746 1/20 0.35
MAPT P10636 1/20 0.35
NR1H4 Q96RI1 1/20 0.34
MAOA P21397 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16455298 0.91 S1PR1 (0.43) S1PR1CA2CA9CA12CA1
SCHEMBL16455300 0.90 S1PR1 (0.44) S1PR1CA2CA9CA12CA1
SCHEMBL19628303 0.88 NPC1 (0.48) NPC1L3MBTL1RAB9AKMT2ATP53
SCHEMBL16455486 0.86 ALDH1A1 (0.39) CA2CA9CA1HSP90AA1NPC1
SCHEMBL16455392 0.83 NR1H2 (0.41) S1PR1CA2CA9CA12CA1
SCHEMBL16455514 0.82 S1PR1 (0.44) S1PR1CA2CA9CA12CA1
SCHEMBL16455252 0.82 NR1H2 (0.46) S1PR1CA2CA9CA12CA1
SCHEMBL16455491 0.81 HSP90AA1 (0.39) HSP90AA1HSP90B1TRAP1RXRANR1H2
SCHEMBL16455659 0.80 NR1H2 (0.49) S1PR1CA2CA9CA12CA1
SCHEMBL16455605 0.79 RXRA (0.53) S1PR1CA2CA9CA12CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170334897-A1 Liver X Receptor (LXR) Modulators For The Treatment Of Dermal Diseases, Disorders And Conditions ALEXAR THERAPEUTICS, INC. 2017-11-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170334897-A1 Liver X Receptor (LXR) Modulators For The Treatment Of Dermal Diseases, Disorders And Conditions NR1H2, NR1H3, RXRA S1PR1 511/4885CA2 4844/4885CA9 4728/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.